Bretylium abolishes neurotransmitter release without necessarily abolishing the nerve terminal action potential in sympathetic terminals by Brain, Keith & Cunnane, TC
 
 
Bretylium abolishes neurotransmitter release
without necessarily abolishing the nerve terminal
action potential in sympathetic terminals
Brain, Keith; Cunnane, TC
DOI:
10.1038/sj.bjp.0707623
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Brain, K & Cunnane, TC 2008, 'Bretylium abolishes neurotransmitter release without necessarily abolishing the
nerve terminal action potential in sympathetic terminals', British Journal of Pharmacology, vol. 153, no. 4, pp.
831-839. https://doi.org/10.1038/sj.bjp.0707623
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Wiley Gold article. This version is published in British Journal of Pharmacology
Volume 153, Issue 4, pages 831–839, February 2008
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
RESEARCH PAPER
Bretylium abolishes neurotransmitter release
without necessarily abolishing the nerve terminal
action potential in sympathetic terminals
KL Brain and TC Cunnane
Department of Pharmacology, University of Oxford, Oxford, UK
Background and purpose: The antidysrhythmic bretylium is useful experimentally because it selectively abolishes
neurotransmitter release from sympathetic peripheral nerve terminals. Its mechanism of action seemed settled, but recent
results from optical monitoring of single terminals now suggests a new interpretation.
Experimental approach: Orthograde transport of a dextran-conjugated Ca2þ indicator to monitor Ca2þ in nerve terminals of
mouse isolated vas deferens with a confocal microscope. In some experiments, local neurotransmitter release was detected by
monitoring neuroeffector Ca2þ transients (NCTs) in adjacent smooth muscles, a local measure of purinergic transmission.
Sympathetic terminals were identified with catecholamine fluorescence (UV excitation) or post-experiment immunohisto-
chemistry.
Key results: Bretylium (10mM) abolished NCTs at 60/61 junctions over the course of 2 h, indicating effective abolition of
neurotransmitter release. However, bretylium did not abolish the field stimulus-induced Ca2þ transient in most nerve
terminals, but did increase both action potential delay (by 2±0.4ms) and absolute refractory period (by 4±2ms).
Immunohistochemistry demonstrated that 85–96% of terminals orthogradely filled with a dextran-conjugated fluorescent
probe contained Neuropeptide Y (NPY). A formaldehyde–glutaraldehyde-induced catecholamine fluorescence (FAGLU)
technique was modified to allow sympathetic terminals to be identified with a Ca2þ indicator present. Most terminals
contained catecholamines (based on FAGLU) or secrete ATP (as NCTs in adjacent smooth muscle cells are abolished).
Conclusions and implications: Bretylium can inhibit neurotransmitter release downstream of Ca2þ influx without abolishing
the nerve terminal action potential. Bretylium-induced increases in the absolute refractory period permit living sympathetic
terminals to be identified.
British Journal of Pharmacology (2008) 153, 831–839; doi:10.1038/sj.bjp.0707623; published online 10 December 2007
Keywords: sympathetic; confocal; calcium; bretylium; vas deferens; mouse
Abbreviations: FAGLU, formaldehyde–glutaraldehyde-induced catecholamine fluorescence; NCT, neuroeffector Ca2þ transient;
Oregon-BAPTA-dex, Oregon Green 488 BAPTA-1 10kDa dextran
Introduction
The mouse vas deferens is a useful model for studying
sympathetic transmission as it has a dense, but not exclusive,
noradrenergic innervation (Sjo¨strand, 1965; Taxi, 1965;
Yamauchi and Burnstock, 1969; Jones and Spriggs, 1975).
With the increasing use of optical techniques to study living
autonomic terminals (Brain and Bennett, 1997; Jackson
et al., 2001; Lamont et al., 2003), it is now necessary to
identify nerve terminal types in living tissue or at least to be
able to identify the nerve terminal type on the stage of the
microscope. The Falck technique (Falck et al., 1962) allowed
catecholamines to be detected using light microscopes and
was used to show that there is a dense noradrenergic
innervation in rodent vasa deferentia (Sjo¨strand, 1965),
particularly in mice (Taxi, 1965; Jones and Spriggs, 1975).
Sympathetic terminals can also be identified by the detec-
tion of intraterminal granular vesicles in electron micro-
graphs (Merrillees et al., 1963; Richardson, 1966) or with
immunohistochemistry. However, the extensive tissue pro-
cessing required complicates all of these experimental
approaches.
It has been shown, in mouse vas deferens (Brain et al.,
2002, 2003), rat mesenteric vessels (Lamont and Wier, 2002)
and rat urinary bladder (Heppner et al., 2005), that the focal
release of ATP acting on postjunctional P2X1 receptors can
be detected by optically monitoring the Ca2þ concentration
in smooth muscle cells. In the mouse vas deferens, the focal
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Ca2þ transients evoked by local ATP release are referred to as
neuroeffector Ca2þ transients (NCTs). Although it has been
assumed that such ATP release arises from sympathetic
terminals, the bretylium sensitivity of these events has not
yet been established.
It has been argued that bretylium (Boura and Green, 1959)
prevents neurotransmitter release from sympathetic nerve
terminals by abolishing the nerve terminal action potential
(Haeusler et al., 1969; Mitchell and Oates, 1970; Maxwell and
Wastila, 1977; Brock and Cunnane, 1988); selectivity for
sympathetic terminals occurs because bretylium is taken up
into sympathetic terminals by a norepinephrine (NA)
transporter-1 (or uptake-1). Hence, a potentially useful
approach to identify noradrenergic terminals is to detect
strings of varicosities in which the nerve action potential is
abolished by bretylium (Jackson and Cunnane, 2002).
However, Jackson and Cunnane (2002) showed that brety-
lium (20 mM) does not abolish the action potential-induced
Ca2þ transient in the majority of nerve terminal varicosities
orthogradely loaded with the dextran conjugate of a Ca2þ
indicator. This causes a dilemma because the innervation of
the mouse vas deferens is predominantly sympathetic (Taxi,
1965; Jones and Spriggs, 1975). Potential explanations
include that
(a) the outer longitudinal layer was predominantly inner-
vated by non-sympathetic nerves;
(b) the dextran-conjugated Ca2þ indicator selectively loads
non-sympathetic terminals;
(c) the dextran-conjugated Ca2þ indicator selectively loads
non-secretory regions of sympathetic terminals located
proximally within the nerve terminal arborization;
(d) bretylium changes the shape of the nerve terminal
action potential (and hence the configuration of the
nerve terminal impulse) so that, although the total Ca2þ
influx is not changed, the spatiotemporal Ca2þ pattern
close to the membrane changes sufficiently to abolish
transmitter release;
(e) bretylium inhibits transmitter release downstream of
Ca2þ influx.
In the present study, hypotheses (a) and (b) are explored
using immunohistochemistry, secretory terminals are iden-
tified on the basis of the action of bretylium on NCTs (c),
whereas (d) and (e) are addressed using line scanning
confocal Ca2þ imaging in nerve terminals. In addition, 3
methods for identifying sympathetic terminals in intact
organs will be compared, namely the formaldehyde–glutar-
aldehyde-induced catecholamine fluorescence (FAGLU)
technique, bretylium-induced action potential delay and
the suppression of NCTs by bretylium.
Methods
Orthograde loading of nerve terminals
Vasa deferentia were removed from 8- to 12-week-old Balb/c
mice (Harlan, UK), which had been killed by cervical
fracture. Experiments were in accordance with the European
Communities Council Directives (86/609/EEC of 24
November 1986). Each vas deferens was transferred to an
organ bath; the cut prostatic end of each vas deferens was
secured in a glass micropipette containing the 10 kDa
dextran conjugate of either Alexa 568 or the Ca2þ indicator
Oregon Green 488 BAPTA-1 (Oregon-BAPTA (1,2-bis(O-
aminophenoxy)ethane-N,N,N0,N0-tetracetic acid)-dex; Invitro-
gen, Paisley, UK), using a protocol similar to that previously
described (Brain and Bennett, 1997). The bathing physiological
salt solution was re-circulated and contained (mM) NaCl 118.4,
NaHCO3 25.0, NaH2PO4 1.13, CaCl2 1.8, KCl 4.7, MgCl2 1.3 and
glucose 11.1. pH and [O2] were regulated by continuously
bubbling the solution reservoir with 95% O2/5% CO2. The
preparations were left in contact with the dye for 5h, removed
from the micropipette and then left for a further 5h, all at room
temperature.
Immunohistochemistry
After orthogradely loading nerve terminals with Alex 568
dextran, vasa deferentia were fixed in 3% paraformaldehyde
for 2h and then cut using a vibratome to a thickness of 30–
50 mm. Primary antibodies (raised in rabbit) were applied at a
dilution of 1:1000 in 0.1% Triton X-100, overnight at 4 1C.
The sections were then washed three times (10min for each
wash), and then incubated with Alexa 488-conjugated goat
anti-rabbit secondary antibody (1:200) for 6–8h at room
temperature. The sections were washed a further three times,
before being mounted on a slide in Vectashield (Vector
Laboratories, Peterborough, UK). The primary antibodies
used were rabbit polyclonal antibodies for Neuropeptide Y
(NPY) (catalogue number NA1233; Affiniti, Devon, UK),
Calcitonin gene related peptide (CGRP; CA1134), TH
(TZ1010) and the vesicular ACh transporter (H-120; Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA). This NPY
antibody has not been confirmed to work in mice. However,
the amino-acid sequence of NPY is the same in mouse (Swiss
Prot accession number P57774; positions 29–64), human
(accession number P01303; 29–64) and rat (accession
number P07808; 30–65). In preliminary experiments using
a primary rabbit polyclonal IgG against the vesicular ACh
transporter (H-160; Autogen Bioclear UK (Calne, Wiltshire,
UK)), there was no positive labelling in either the vas
deferens or the bladder (which contains a dense cholinergic
innervation and hence acts as a positive control). Given the
lack of labelling in the bladder vesicular, ACh transporter
labelling was not used to investigate the cholinergic
innervation of the vas deferens. In mouse bladder, dense
AChE labelling could be detected (results not shown). To
reduce the impact of poor antibody penetration into these
sections, confocal images were acquired only within 5 mm of
the cut surfaces.
FAGLU
The FAGLU technique (Furness et al., 1978) allows the
detection of catecholamines in nerve terminals and is a
modification of the histochemical technique of Hillarp
and Falck (Falck et al., 1962). The only naturally occurring
substances in peripheral nerves that generate a fluorescent
product when reacted with aldehydes are noradrenaline,
adrenaline, dopamine and 5-HT; these are only found in
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sympathetic nerves and their terminals (Furness et al., 1978),
although 5-HT may be found in other cell types such as mast
cells. In the present study, a modification of the original
FAGLU technique was used (Furness et al., 1987). At the end
of the experiments in living organs, a solution containing
4% formaldehyde and 0.5% glutaraldehyde in 0.1M sodium
phosphate buffer (adjusted to pH 7.0) was cooled at 0 1C and
applied to the vas deferens while in an organ bath mounted
on the stage of a confocal microscope. The solution was
changed every 20min to keep the temperature low. The
solution was then changed to one containing FAGLU (as
above) with 20% w/v sucrose (Nakamura, 1979). The
chemistry of this reaction is described elsewhere (Bjo¨rklund
et al., 1973). The ultraviolet (UV) laser on the confocal
microscope was used to excite fluorescence. In tissues loaded
with Oregon-BAPTA-dex, UV illumination excited a fluor-
escent signal from dextran-loaded terminals when a 515nm
long pass emission filter was used. Hence, all experiments
involving UV illumination and Oregon-BAPTA-dex were
carried out using a 440nm band pass emission filter. The
emission spectrum of Oregon-BAPTA-dex when illuminated
with UV light (355nm wavelength) was assessed in a
spectrophotometer (LS50B; Perkin Elmer, Seer Green, UK).
There was a strong, narrow fluorescent peak at 395±20nm
and a weak, broad peak with a maximum at 520nm
(commencing at 485nm); there was negligible fluorescent
emission at 440±20nm. When the FAGLU solution was
added to the cuvette containing Oregon-BAPTA-dex, there
was a 25% increase in the fluorescent signal at 520nm (after
30min), but still there was no fluorescent signal at
440±20nm. This implies that Oregon-BAPTA-dex in FA-
GLU-treated tissue is unlikely to fluoresce at 440±20nm
when excited with the UV laser.
Nerve terminal Ca2þ imaging
In preparations orthogradely loaded with Oregon-BAPTA-dex,
images were acquired using a Leica NT inverted confocal
microscope. Nerve terminals filled with the Ca2þ indicator
and a small number of smooth muscle cells close to the cut
end of the tissue could be seen (Brain et al., 2002). In some
cases, labelled smooth muscle cells were found where the
adjacent nerve terminal varicosities were also filled with the
indicator. All field stimuli (pulse width 0.1ms; amplitude
50V) were synchronized with the start of image acquisition,
so that the interval between each stimulus and recording was
fixed. During line scanning (0.54ms per line for 256 lines,
acquired and stimulated at 0.33Hz for 60 s), stimuli were
triggered 40ms after the commencement of each frame.
Smooth muscle Ca2þ imaging
In these experiments, each vas deferens was exposed to the
Ca2þ indicator Oregon Green 488 BAPTA-1 acetoxymethyl
ester (Oregon-BAPTA-AM; Molecular Probes; 10 mM in 1%
dimethylsulphoxide) for 2h at 36 1C and then washed for at
least 30min in physiological salt solution. This filled several
cell types within the preparation (although almost never
nerve terminals); smooth muscle cells were identified by
their characteristic morphology. During field stimulation,
highly intermittent, focal smooth muscle Ca2þ transients
(NCTs) were recorded as described previously (Brain et al.,
2002).
Image analysis
Image analysis was performed with NIH Image 1.63 (http://
rsb.info.nih.gov/nih-image/) or Image SXM (http://www.
liv.ac.uk/~sdb/ImageSXM/) using custom-written macros.
Nerve terminal and smooth muscle Ca2þ measurements
were quantified as described previously (Brain and Bennett,
1997; Brain et al., 2002).
Drug preparation
Bretylium tosylate and amphetamine sulphate stock solu-
tions (10mM in water; Sigma-Aldrich (Poole, Dorset, UK))
were stored in aliquots at –20 1C. Formaldehyde (F8775;
37%) and glutaraldehyde solutions (G5882; 25%; Sigma)
were diluted to the appropriate final concentration when
required.
Statistics
In the immunohistochemistry and FAGLU experiments, 95%
confidence intervals (95% CIs) were calculated by assuming
that terminals were randomly selected from the population
(and hence that counting followed binomial statistics).
Results
Immunohistochemistry
To identify the types of nerve terminal in the outer
longitudinal layer of the mouse vas deferens accessible to
orthograde labelling, terminals were loaded with Alexa 568
dextran, fixed and longitudinal sections were taken for
immunohistochemistry. TH labelling was detected in at least
two varicosities per terminal in 39 of the 81 dextran-labelled
terminals (95% CI 39–59%). In many terminals, only a small
proportion of the varicosities were positively labelled with
TH (Figure 1a). In sections labelled with NPY, which also
marks sympathetic terminals, 82 of the 90 terminals were
NPY positive (95% CI 85–96%; Figure 1b).
From a sample of 91 terminals, five were CGRP positive
(95% CI 3–12%; Figure 1c). Although the CGRP labelling was
punctate, the terminals themselves, filled with an indicator
that distributes throughout the cytoplasm, had a smoother
profile than that seen with TH- or NPY-positive terminals.
In other tissues, 19 of the 312 terminals were AChE
positive (95% CI 4–9%; Figure 1d). These AChE-positive
terminals were often located in tight loops reminiscent of
small blood vessels supplying the vas deferens.
FAGLU labelling
The FAGLU labelling technique was used to identify
catecholamine-containing nerve terminals. Each vas deferens
was exposed to FAGLU for 30–60min. During this time, no
specific fluorescence could be observed when excited with
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488nm light (Figure 2a), but with UV excitation structures
resembling nerve terminal varicosities could be identified
(Figure 2b).
To determine whether dextran-labelled terminals con-
tained catecholamines, vasa deferentia were orthogradely
loaded with Oregon-BAPTA-dex. Terminals (Figure 2c) were
identified in which field stimulation caused an increase in
fluorescent signal, indicating an increase in [Ca2þ ]t. When
these live vasa deferentia were viewed with UV illumination
(using a 440nm band pass emission filter), there was
significant tissue autofluorescence (Figure 2d). No nerve
terminals could be identified. When FAGLU was added to
the bath, there was some local tissue deformation and
rotation, but this was not sufficient to either lose the field of
view or prevent the identification of each nerve terminal.
The location of each nerve terminal was identified with
488nm wavelength light (for example, see Figure 2e). When
exciting fluorescence with UV light, a fluorescent signal
developed in 113 of the 117 nerve terminals (93–99%;
number of preparations, np¼7; for example, see Figure 2f).
Many terminals were fluorescent under UV illumination, but
not when excited at 488nm, implying that not all terminals
in the preparation were filled with the Ca2þ indicator (or
were poorly filled). It was possible to identify terminals that
were filled with the dextran, but showed no UV fluorescence
after treatment with FAGLU (Figures 2g and h).
Bretylium and FALGU
Nerve terminals orthogradely loaded with OG-BAPTA-dex
and responding to field stimulation were identified. When
exposed to bretylium (10–20mM) for 2h, all terminals
recorded in this series maintained their nerve terminal
[Ca2þ ]t transient elicited by field stimulation (19 terminals;
np¼5). Upon exposure to FAGLU, all of these terminals
developed a UV fluorescent signal.
Bretylium and NCTs
In preparations loaded with Oregon-BAPTA-AM, to fill
smooth muscle cells with the Ca2þ indicator, field stimula-
tion at 1Hz was used to elicit NCTs. Bretylium (10 mM)
abolished almost all evoked NCTs (number of neuroeffector
junctions, nj¼60/61; np¼7; for example, see Figure 3). This
effect was partially reversed by 10 mM amphetamine (to at
least 10% of the control frequency), a drug that inhibits
intraterminal bretylium accumulation (Ross and Gosztonyi,
1975). At the one junction where bretylium did not abolish
NCTs, their frequency was reduced by more than 90%, and
amphetamine (10 mM) caused complete recovery of NCTs (to
within 10% of the control frequency).
In experiments where both nerve terminal varicosities and
the underlying smooth muscle cells were loaded (using
Oregon-BAPTA-dex), it was possible to record the nerve
terminal Ca2þ transient and directly adjacent NCTs (Figure 3;
np¼3). In such cases, NCTs were abolished without abolish-
ing the nerve terminal action potential.
Bretylium and the nerve terminal Ca2þ transient
Nerve terminal varicosities were loaded with Oregon-BAPTA-
dex to measure the delay between the stimulus and a rapid
rise in [Ca2þ ]t during line scanning confocal microscopy
(which acts a proxy for the arrival of the action potential).
After 60–90min in bretylium (10 mM), the delay was in-
Figure 1 Immunohistochemistry of orthogradely loaded terminals.
The left panels show a selection of terminals orthogradely loaded
with Alexa 568 dextran from fixed tissue cut in longitudinal sections.
The right panels show the corresponding regions in experiments in
which the sections were labelled with TH (a), NPY (b), CGRP (c) or
AChE (d). CGRP, Calcitonin gene related peptide; NPY, Neuropep-
tide Y.
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creased by 2±0.4ms (np¼7; Figure 4a); an increased delay
was observed in all terminals. No significant change in the
rise time or the recovery of the [Ca2þ ]t transient was
detected. The onset of this increased delay commenced
60min after the first exposure to bretylium (Figure 4b).
The refractory period in single nerve terminals was
measured using paired-pulse supramaximal field stimuli
and monitoring [Ca2þ ]t. Under control conditions, the
absolute refractory period was 3ms in all terminals tested
(Figure 4c); that is paired pulse stimuli could not be elicited
with a 2ms delay, but could be elicited with a 3ms delay
between the pulses. After treatment with bretylium (10 mM)
for 90min, the refractory period was 7±2ms (in 7 terminals;
np¼3; Figure 4d). The refractory period increased by at least
1ms in all terminals. It was noted that even under control
conditions, the time between the increase in [Ca2þ ]t
from consecutive field stimuli was slower than the
interpulse interval (Figure 4c). This is consistent with a
slower propagation speed of the second action potential in
the pair.
Figure 2 FAGLU fluorescence in the outer longitudinal layer. In the absence of nerve terminal Oregon-BAPTA-dex labelling and after the
FAGLU protocol, 488nm light excitation gives little fluorescence. (a) When excited with a UV laser (b), nerve terminal varicosities fluoresce. (c)
A wide field image of Oregon-BAPTA-dex-filled terminals (for example, at the arrow) illuminated at 488nm prior to the FAGLU protocol. When
the same region is illuminated with UV light (d), there is significant autofluorescence from an unidentified cell types or structures. There is no
UV fluorescent signal from terminals. After treatment with FAGLU, there is some degree of tissue deformation and an increase in the fluorescent
signal in terminals excited at 488nm. (e) When illuminated with UV light (f), many nerve terminal fluoresce, including some that are not (or
that are poorly) filled with the Ca2þ indicator (arrowhead). (g and h) Another field, where there are Oregon-BAPTA-dex-filled terminals that
are both FAGLU positive (arrow) and FAGLU negative (arrowhead). BAPTA , 1,2-bis(O-aminophenoxy)ethane-N,N,N,0N-tetracetic acid; FAGLU,
formaldehyde–glutaraldehyde-induced catecholamine fluorescence; Oregon-BAPTA-dex, Oregon Green 488 BAPTA-1 10 kDa dextran.
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Discussion and conclusions
In the guinea pig vas deferens, bretylium abolishes excitatory
junction currents and markedly alters the shape of the nerve
terminal impulse (Brock and Cunnane, 1988), an effect that
has been interpreted as indicating an abolition of the nerve
terminal action potential (for review see Boura, 1997). In the
mouse vas deferens, bretylium abolishes excitatory junction
potentials, but does not affect the nerve terminal Ca2þ
transients in the majority of terminals in this tissue (Jackson
and Cunnane, 2002); this apparent contradiction is explored
in the present work.
The finding that bretylium abolishes NCTs (in the majority
of cases) implies that NCTs arise from the release of ATP from
sympathetic terminals. As such, the occurrence of NCTs
adjacent to nerve terminal varicosities can be used to identify
a given varicosity as sympathetic. The main problem with this
approach is that in many sympathetically innervated tissues,
neurotransmitter release occurs from within small bundles of
terminals. In such cases, if different nerve terminal types are
closely packed together, it may be impossible to use this
optical approach to identify the source of the neurotransmit-
ter. In the mouse vas deferens, sympathetic nerve terminals
commonly run singly (Cottee et al., 1996).
Bretylium had no detectable effect on either the time
course of the action potential-induced [Ca2þ ]t rise or the rate
of [Ca2þ ]t recovery. This supports the evidence of Jackson
and Cunnane (2002) that bretylium does not affect Ca2þ
handling in nerve terminals. However, the increase in delay
between the stimulus and arrival of the action potential in
the nerve terminal (as reported by an increase in [Ca2þ ]t)
suggests that either the site of action potential initiation
moves further away from the terminal or, more likely, that
the speed of action potential propagation has slowed. The
increase in absolute refractory period fits well with the
classical observation that the effects of bretylium are more
marked on high-frequency stimulation (Boura and Green,
1962) and represents the local anaesthetic-like action of
Figure 3 Nerve terminal [Ca2þ ] regulation, neuroeffector Ca2þ transients (NCTs) and bretylium. (a) A set of images, acquired every 500ms,
showing an Oregon-BAPTA-dex-labelled smooth muscle cell and nerve terminal varicosities (for example, at the arrows). Every field stimulus (#)
resulted in an increase in [Ca2þ ]t, but only intermittent evoked local increases in [Ca
2þ ] in the smooth muscle cell (NCTs; for example on
the 4th and 6th frames, marked with an asterisk). After 90min in bretylium, the [Ca2þ ]t increased upon every field stimulus; however, no NCTs
were detected. (b) A wider field view of this region (average of 400 frames; frames were aligned with Image SXM prior to averaging). Maps of
the location of NCTs, occurring at some time over 30min of recording, were constructed under both control conditions (d) and after exposure
to bretylium (e). (d and e) A manually drawn cell outline (from c and f, respectively) as an aid for aligning corresponding areas. (f) An average
of 10 frames, acquired at a slightly different plane of focus to demonstrate some nerve terminal varicosities that are not in the plane of focus in
(c). BAPTA , 1,2-bis(O-aminophenoxy)ethane-N,N,N,0N-tetracetic acid; Oregon-BAPTA-dex, Oregon Green 488 BAPTA-1 10 kDa dextran.
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bretylium that is specific to sympathetic nerves (Haeusler
et al., 1969; Brock and Cunnane, 1988). The nerve terminal
impulse, the second derivative of the action potential, is
expected to change greatly with action potential slowing;
therefore, it is possible that the nerve terminal impulse
amplitude change described by Brock and Cunnane (1988)
might be due purely to slowing rather than to a collapse of
the nerve terminal action potential. An increase in absolute
refractory period induced by bretylium could be used to
optically identify sympathetic nerve terminals during nerve
terminal [Ca2þ ] imaging.
The abolition of NCTs without abolishing the nerve
terminal action potential in the adjacent terminal and the
high proportion of catecholamine-containing terminals in
which bretylium fails to abolish the nerve terminal Ca2þ
transient, together imply that bretylium can inhibit neuro-
transmitter release without abolishing the nerve terminal
action potential, at least in the mouse vas deferens. Whether
this is by changing the shape of the nerve terminal action
potential (in a manner that does not significantly affect
Ca2þ influx), by locally modifying the spatiotemporal Ca2þ
signal at the trigger site in a manner that does not affect the
residual Ca2þ transient (hypothesis d) or by targeting
exocytosis at a site downstream of Ca2þ entry (hypothesis
e) has not been clearly established. Further evidence for a
direct action of bretylium on transmitter release comes from
chick sympathetic neurons, where bretylium (3 mM) can
abolish norepinephrine overflow while having no effect on
depolarization-induced Ca2þ current (under voltage clamp)
or intracellular [Ca2þ ] transient during action potentials
(evoked by 120mA current pulses for 1ms applied at 1Hz for
10 s) (Przywara et al., 1991). Also, cooling-induced release of
noradrenaline from cutaneous blood vessels (and hence
vasoconstriction) is present in tetrodotoxin (TTX), but
blocked by the addition of bretylium (Koganezawa et al.,
2006). This suggests that bretylium, in addition to its effects
on nerve terminal conduction, blocks noradrenaline release
downstream of the action potential.
It seems odd that in the present experiments, the TH
labelling was not consistent within a given terminal. The
most parsimonious explanation is that of a methodological
problem of poor permeability of the primary TH antibody
into the tissue. Such non-uniformity was not present in the
labelling with other primary antibodies such as that for NPY.
In addition to nerve terminals, NPY immunoreactivity has
been detected in Schwann cells (Ubink and Hokfelt, 2000).
However, in the present immunohistochemistry experi-
ments, varicosities were identified by othogradely loading
with the dextran conjugate of Alexa 568 so that terminals
could be morphologically identified.
Although NPY labelling has been used to identify sympa-
thetic nerves (Stja¨rne et al., 1986; Ventura et al., 1998), there
is a very low density of cholinergic terminals that contain
both vasoactive intestinal peptide (VIP) and NPY in the
guinea pig vas deferens (Song et al., 1994). If it is assumed
that AChE marks cholinergic terminals and CGRP locates
sensory terminals, the distribution of terminal types in the
outer longitudinal layer was broadly in line with that
reported for whole mouse vas deferens (Sjo¨strand, 1965;
Taxi, 1965; Yamauchi and Burnstock, 1969; Jones and
Spriggs, 1975). These observations suggest that dextran-
conjugated fluorescent probes do not selectively load any
particular nerve terminal type. In the mouse vas deferens,
only about 10% of axons are cholinergic (Yamauchi and
Burnstock, 1969; Jones and Spriggs, 1975). Although the
distribution of cholinergic fibres has not been clearly
described in the mouse, in other rodents the cholinergic
fibres are concentrated in the inner circular layer close to the
epithelium (Risley and Skrepetos, 1964; Al-Zuhair et al.,
1975; Ventura et al., 1998).
The observation that 93–99% of terminals developed UV-
induced fluorescence in response to FAGLU is consistent
with the observation that most 3,3-diethyloxardicarbocya-
nide (DiOC2(5)) fluorescent varicosities in the mouse vas
deferens also display such FAGLU fluorescence (Lavidis and
Bennett, 1993). It is worth noting that the UV laser is capable
of eliciting some fluorescent signal from the Ca2þ indicator
Oregon-BAPTA-dex at long wavelengths. However, by sam-
pling the fluorescent emission signal with a band pass
440nm filter, it is possible to detect only the catecholamine-
induced fluorescent signal. The density of varicosities in the
Figure 4 Line scanning Ca2þ imaging in nerve terminals with and
without bretylium. (a) The average of four confocal line scans
through a single terminal, with and without bretylium, showing
the change in the fluorescent signal (DF/F) of the Ca2þ indicator
Oregon-BAPTA-dex. A single field stimulus was applied at 0ms, and
after a brief delay the nerve terminal action potential arrives in the
terminal, causing an increase in [Ca2þ ]t. In the presence of
bretylium, the [Ca2þ ]t rises later, suggesting that the action
potential arrives in the terminal later. The time taken for the onset
of this delay is illustrated in (b), which represents the delay between
the stimulus and first detectable increase in [Ca2þ ]t in a single
terminal. In a different preparation (c and d), supramaximal paired-
pulse stimuli (arrows) were applied to measure the absolute
refractory period. Each trace is the average of four line scans
acquired before (c) and in the presence (d) of bretylium. Note in (c)
the second pulse at a 2ms interval fails to initiate an increase in
[Ca2þ ]t (suggesting that it fails to initiate an action potential or that
any action potential fails to reach the terminal), but does transmit at
a 3ms interval. In the presence of bretylium, the second impulse will
not transmit at a 4ms (or briefer) interval, but will do so at a 5ms (or
longer) interval. BAPTA , 1,2-bis(O-aminophenoxy)ethane-N,N,N,0N-
tetracetic acid; Oregon-BAPTA-dex, Oregon Green 488 BAPTA-1
10 kDa dextran.
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vas deferens of 2# 106mm$3 (56#106 per 10mm length in
the rat; Dahlstro¨m et al., 1966; cross-sectional muscle area of
2.6mm2; Carvalho et al., 1993) implies that about four
varicosities per 30 mm#30 mm#2 mm optical section should
be observed. This is comparable to or lower than the density
of FAGLU-positive varicosities observed in the present study
(see Figure 2).
A limitation of the present study is that the high
proportion of sympathetic terminals makes it difficult to
find non-sympathetic terminals. Hence, it is not surprising
that no terminals were found in which bretylium failed to
affect the absolute refractory period.
Although FAGLU, juxtaposition of terminals and NCTs,
and bretylium-induced refractory period prolongation have
been shown to be viable methods for identifying catechola-
minergic terminals in the mouse vas deferens, FAGLU seems
the simplest approach in the absence of nerve terminal Ca2þ
imaging, whereas bretylium-induced refractory period pro-
longation has the advantage of allowing living terminals to
be identified when nerve terminal Ca2þ imaging is available.
The direct mode of action of bretylium to inhibit neuro-
transmitter release, independent of effects on the nerve
terminal action potential, should be considered when it is
used as an investigational tool.
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